Abstract
Allergic diseases, such as allergic asthma, allergic rhinitis, atopic dermatitis, conjunctivitis, urticaria, food allergy, and/or anaphylaxis, are associated with the skewing of immune responses towards a T helper 2 (TH2) phenotype, resulting in eosinophilic inflammation. TH2 cytokines, such as interleukin (IL)-4, IL-5 and IL-13, promote IgE production, mast cell differentiation, and eosinophil growth, migration and activation which then lead to the pathologic abnormalities in allergic diseases. Moreover, the impaired function of regulatory T cells has been noted in allergic diseases. To date, treatments for allergic diseases, such as antihistamines, corticosteroids, bronchodilators and some allergen-specific immunotherapy, are effective but costly and require long-term and recurrent drug administration. Gene therapy has been shown to be an easy, effective, and convenient treatment by delivering the allergen or the therapeutic protein in the form of plasmid DNA in vivo to modulate allergic immune responses. We summarize here the recent advances of gene therapy in allergic diseases and discuss the challenges in clinical application.
Keywords: Gene therapy, Allergic disease, TH2, Allergen-specific immunotherapy, Regulatory T cell, Cytokine, Viral vector
Current Gene Therapy
Title: Gene Therapy for Allergic Diseases
Volume: 9 Issue: 3
Author(s): Ya-Hui Chuang, Yao-Hsu Yang, Si-Jie Wu and Bor-Luen Chiang
Affiliation:
Keywords: Gene therapy, Allergic disease, TH2, Allergen-specific immunotherapy, Regulatory T cell, Cytokine, Viral vector
Abstract: Allergic diseases, such as allergic asthma, allergic rhinitis, atopic dermatitis, conjunctivitis, urticaria, food allergy, and/or anaphylaxis, are associated with the skewing of immune responses towards a T helper 2 (TH2) phenotype, resulting in eosinophilic inflammation. TH2 cytokines, such as interleukin (IL)-4, IL-5 and IL-13, promote IgE production, mast cell differentiation, and eosinophil growth, migration and activation which then lead to the pathologic abnormalities in allergic diseases. Moreover, the impaired function of regulatory T cells has been noted in allergic diseases. To date, treatments for allergic diseases, such as antihistamines, corticosteroids, bronchodilators and some allergen-specific immunotherapy, are effective but costly and require long-term and recurrent drug administration. Gene therapy has been shown to be an easy, effective, and convenient treatment by delivering the allergen or the therapeutic protein in the form of plasmid DNA in vivo to modulate allergic immune responses. We summarize here the recent advances of gene therapy in allergic diseases and discuss the challenges in clinical application.
Export Options
About this article
Cite this article as:
Chuang Ya-Hui, Yang Yao-Hsu, Wu Si-Jie and Chiang Bor-Luen, Gene Therapy for Allergic Diseases, Current Gene Therapy 2009; 9 (3) . https://dx.doi.org/10.2174/156652309788488604
DOI https://dx.doi.org/10.2174/156652309788488604 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Airway Smooth Muscle Cell as Therapeutic Target of Inflammation
Current Medicinal Chemistry Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Fluorescent Probes for Cellular Assays
Combinatorial Chemistry & High Throughput Screening Thyroid Diseases During Pregnancy: Bibliometric Analysis of Scientific Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Lymphotoxin Receptor Signaling in Diseases
Current Molecular Medicine Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
CNS & Neurological Disorders - Drug Targets Nanocarriers in Improved Heparin Delivery: Recent Updates
Current Pharmaceutical Design Nasal <i>In-situ</i> Gel: An Approach to Enhance Therapeutic Benefits of the Drug
Drug Delivery Letters Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery IL-4 and IL-13: Their Pathological Roles in Allergic Diseases and their Potential in Developing New Therapies
Current Drug Targets - Inflammation & Allergy The Glucocorticoid Receptor: Molecular Mechanism and New Therapeutic Opportunities
Current Drug Targets - Inflammation & Allergy Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry The Discovery of VLA-4 Antagonists
Current Topics in Medicinal Chemistry Carbon Monoxide: Medicinal Chemistry and Biological Effects
Current Medicinal Chemistry Diagnosis, Prevention and Treatment of Aspirin-Induced Asthma and Rhinitis
Current Drug Targets - Inflammation & Allergy Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design